The role of eukaryotic translation initiation factor 6 in tumors (Review)

Zhu,Wei; Li,Gui Xian; Chen,Hong Lang; Liu,Xing Yan

doi:10.3892/ol.2017.6161

The role of eukaryotic translation initiation factor 6 in tumors (Review)

Authors:
- Wei Zhu
- Gui Xian Li
- Hong Lang Chen
- Xing Yan Liu
View Affiliations

Affiliations: Department of Pathology, Guangdong Medical University, Dongguan, Guangdong 523808, P.R. China, Department of Pharmacology, Guangdong Medical University, Dongguan, Guangdong 523808, P.R. China, Sino‑American Cancer Research Institute, Guangdong Medical University, Dongguan, Guangdong 523808, P.R. China
Published online on: May 12, 2017 https://doi.org/10.3892/ol.2017.6161
Pages: 3-9
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Eukaryotic translation initiation factor 6 (eIF6) affects the maturation of 60S ribosomal subunits. Found in yeast and mammalian cells, eIF6 is primarily located in the cytoplasm of mammalian cells. Emerging evidence has demonstrated that the dysregulated expression of eIF6 is important in several types of human cancer, including head and neck carcinoma, colorectal cancer, non‑small cell lung cancer and ovarian serous adenocarcinoma. However, the molecular mechanisms by which eIF6 functions during tumor formation and progression remain elusive. The present review focuses on recent progress in terms of the mechanisms and functions of eIF6 in human tumorigenesis or cancer cell lines, along with the signal transduction pathways in which this novel translation initiation factor may participate. Oncogenic Ras activates Notch‑1 and promotes transcription of eIF6 via a recombining binding protein suppressor of Hairless‑dependent mechanism. In addition, overexpression of eIF6 results in aberrant activation of the Wnt/β‑catenin signaling pathway. Similarly, overexpressed eIF6 regulates its downstream modulator, cell division control protein 42, which in turn affects oncogenesis. Finally, the potential of eIF6 as a biomarker for diagnosis of cancer is also discussed in the present review.

View Figures

View References

1	Russell DW and Spremulli LL: Mechanism of action of the wheat germ ribosome dissociation factor: Interaction with the 60 S subunit. Arch Biochem Biophys. 201:518–526. 1980. View Article : Google Scholar : PubMed/NCBI
2	Finch AJ, Hilcenko C, Basse N, Drynan LF, Goyenechea B, Menne TF, González Fernández A, Simpson P, D'Santos CS, Arends MJ, et al: Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome. Genes Dev. 25:917–929. 2011. View Article : Google Scholar : PubMed/NCBI
3	Gartmann M, Blau M, Armache JP, Mielke T, Topf M and Beckmann R: Mechanism of eIF6-mediated inhibition of ribosomal subunit joining. J Biol Chem. 285:14848–14851. 2010. View Article : Google Scholar : PubMed/NCBI
4	Miluzio A, Beugnet A, Grosso S, Brina D, Mancino M, Campaner S, Amati B, de Marco A and Biffo S: Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer Cell. 19:765–775. 2011. View Article : Google Scholar : PubMed/NCBI
5	García-Márquez A, Gijsbers A, de la Mora E and Sánchez-Puig N: Defective guanine nucleotide exchange in the Elongation Factor-Like 1 (EFL1) GTPase by mutations in the Shwachman-Diamond syndrome protein. J Biol Chem. 290:17669–17678. 2015. View Article : Google Scholar : PubMed/NCBI
6	Sanvito F, Vivoli F, Gambini S, Santambrogio G, Catena M, Viale E, Veglia F, Donadini A, Biffo S and Marchisio PC: Expression of a highly conserved protein, p27BBP, during the progression of human colorectal cancer. Cancer Res. 60:510–516. 2000.PubMed/NCBI
7	Biffo S, Sanvito F, Costa S, Preve L, Pignatelli R, Spinardi L and Marchisio PC: Isolation of a novel beta4 integrin-binding protein (p27 (BBP)) highly expressed in epithelial cells. J Biol Chem. 272:30314–30321. 1997. View Article : Google Scholar : PubMed/NCBI
8	Sanvito F, Piatti S, Villa A, Bossi M, Lucchini G, Marchisio PC and Biffo S: The beta4 integrin interactor p27 (BBP/eIF6) is an essential nuclear matrix protein involved in 60S ribosomal subunit assembly. J Cell Biol. 144:823–837. 1999. View Article : Google Scholar : PubMed/NCBI
9	Gandin V, Miluzio A, Barbieri AM, Beugnet A, Kiyokawa H, Marchisio PC and Biffo S: Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation. Nature. 455:684–688. 2008. View Article : Google Scholar : PubMed/NCBI
10	Brina D, Grosso S, Miluzio A and Biffo S: Translational control by 80S formation and 60S availability: The central role of eIF6, a rate limiting factor in cell cycle progression and tumorigenesis. Cell Cycle. 10:3441–3446. 2011. View Article : Google Scholar : PubMed/NCBI
11	Pinzaglia M, Montaldo C, Polinari D, Simone M, La Teana A, Tripodi M, Mancone C, Londei P and Benelli D: EIF6 over-expression increases the motility and invasiveness of cancer cells by modulating the expression of a critical subset of membrane-bound proteins. BMC Cancer. 15:1312015. View Article : Google Scholar : PubMed/NCBI
12	Benelli D, Cialfi S, Pinzaglia M, Talora C and Londei P: The translation factor eIF6 is a Notch-dependent regulator of cell migration and invasion. PLos One. 7:e320472012. View Article : Google Scholar : PubMed/NCBI
13	Rosso P, Cortesina G, Sanvito F, Donadini A, Di Benedetto B, Biffo S and Marchisio PC: Overexpression of p27BBP in head and neck carcinomas and their lymph node metastases. Head Neck. 26:408–417. 2004. View Article : Google Scholar : PubMed/NCBI
14	Tang CL, Yuan SZ, Yang HP, Wang QL and Zhang R: Expression and significance of P311 and ITGB4BP in non-small lung cancer. Zhonghua Zhong Liu Za Zhi. 32:526–528. 2010.(In Chinese). PubMed/NCBI
15	Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne ST, et al: Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol. 21:676–684. 2008. View Article : Google Scholar : PubMed/NCBI
16	Ceci M, Gaviraghi C, Gorrini C, Sala LA, Offenhäuser N, Marchisio PC and Biffo S: Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. Nature. 426:579–584. 2003. View Article : Google Scholar : PubMed/NCBI
17	Biswas A, Mukherjee S, Das S, Shields D, Chow CW and Maitra U: Opposing action of casein kinase 1 and calcineurin in nucleo-cytoplasmic shuttling of mammalian translation initiation factor eIF6. J Biol Chem. 286:3129–3138. 2011. View Article : Google Scholar : PubMed/NCBI
18	Miluzio A, Beugnet A, Volta V and Biffo S: Eukaryotic initiation factor 6 mediates a continuum between 60S ribosome biogenesis and translation. EMBO Rep. 10:459–465. 2009. View Article : Google Scholar : PubMed/NCBI
19	Cruciat CM: Casein kinase 1 and Wnt/b-catenin signaling. Curr Opin Cell Biol. 31:46–55. 2014. View Article : Google Scholar : PubMed/NCBI
20	Schittek B and Sinnberg T: Biological functions of casein kinase 1 isoforms and putative role in tumorigenesis. Mol Cancer. 13:2312014. View Article : Google Scholar : PubMed/NCBI
21	Knippschild U, Kruger M, Richter J, Xu P, García-Reyes B, Peifer C, Halekotte J, Bakulev V and Bischof J: The CK1 family: Contribution to cellular stress response and its role in carcinogenesis. Front Oncol. 4:962014. View Article : Google Scholar : PubMed/NCBI
22	de Marco N, Iannone L, Carotenuto R, Biffo S, Vitale A and Campanella C: p27 (BBP)/eIF6 acts as an anti-apoptotic factor upstream of Bcl-2 during Xenopus laevis development. Cell Death Differ. 17:360–372. 2010. View Article : Google Scholar : PubMed/NCBI
23	de Marco N, Tussellino M, Vitale A and Campanella C: Eukaryotic initiation factor 6 (eif6) overexpression affects eye development in Xenopus laevis. Differentiation. 82:108–115. 2011. View Article : Google Scholar : PubMed/NCBI
24	Silvera D, Formenti SC and Schneider RJ: Translational control in cancer. Nat Rev Cancer. 10:254–266. 2010. View Article : Google Scholar : PubMed/NCBI
25	Atallah AM, Tabll AA, El-Nashar E, El-Bakry KA, El-Sadany M, Ibrahim T and El-Dosoky I: AgNORs count and DNA ploidy in liver biopsies from patients with schistosomal liver cirrhosis and hepatocellular carcinoma. Clin Biochem. 42:1616–1620. 2009. View Article : Google Scholar : PubMed/NCBI
26	Gottwald L, Danilewic M, Fendler W, Suzin J, Spych M, Piekarski J, Tylinski W, Chalubinska J, Topczewska-Tylinska K and Cialkowska-Rysz A: The AgNORs count in predicting long-term survival in serous ovarian cancer. Arch Med Sci. 10:84–90. 2014. View Article : Google Scholar : PubMed/NCBI
27	Lewinska A, Adamczyk J, Pajak J, Stoklosa S, Kubis B, Pastuszek P, Slota E and Wnuk M: Curcumin-mediated decrease in the expression of nucleolar organizer regions in cervical cancer (HeLa) cells. Mutat Res Genet Toxicol Environ Mutagen. 771:43–52. 2014. View Article : Google Scholar : PubMed/NCBI
28	Winzer KJ, Bellach J and Hufnagl P: Long-term analysis to objectify the tumour grading by means of automated microscopic image analysis of the nucleolar organizer regions (AgNORs) in the case of breast carcinoma. Diagn Pathol. 8:562013. View Article : Google Scholar : PubMed/NCBI
29	Gupta V, Garg M, Chaudhry M, Singh S, Sen R, Gill M and Sangwaiya A: Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate. Prostate Int. 2:90–96. 2014. View Article : Google Scholar : PubMed/NCBI
30	Raĭkhlin NT, Bukaeva IA, Smirnova EA, Pavlovskaia AI, Brzhezovskiĭ VZh, Bogatyrev VN and Ponomareva MV: Prognistic value of a study of the expression of argyrophilic nucleolar organizer region associated proteins in case of papillary thyroid cancer. Arkh Patol. 72:49–52. 2010.(In Russian). PubMed/NCBI
31	Mondal NK, Roychoudhury S and Ray MR: Higher AgNOR expression in metaplastic and dysplastic airway epithelial cells predicts the risk of developing lung cancer in women chronically exposed to biomass smoke. J Environ Pathol Toxicol Oncol. 34:35–51. 2015. View Article : Google Scholar : PubMed/NCBI
32	Alaeddini M, Khalili M, Tirgary F and Etemad-Moghadam S: Argyrophylic proteins of nucleolar organizer regions (AgNORs) in salivary gland mucoepidermoid carcinoma and its relation to histological grade. Oral Surg Oral Pathol Oral Radiol Endod. 105:758–762. 2008. View Article : Google Scholar
33	Duvvuri U and Myers JN: Cancer of the head and neck is the sixth most common cancer worldwide. Curr Probl Surg. 46:114–117. 2009. View Article : Google Scholar : PubMed/NCBI
34	Leemans CR, Braakhuis BJ and Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer. 11:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
35	Ferreira MB, De Souza JA and Cohen EE: Role of molecular markers in the management of head and neck cancers. Curr Opin Oncol. 23:259–264. 2011. View Article : Google Scholar : PubMed/NCBI
36	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
37	Peters S, Adjei AA, Gridelli C, Reck M, Kerr K and Felip E; ESMO Guidelines Working Group, : Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23:vii56–vii64. 2012. View Article : Google Scholar : PubMed/NCBI
38	Cetin K, Ettinger DS, Hei YJ and O'Malley CD: Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol. 3:139–48. 2011. View Article : Google Scholar : PubMed/NCBI
39	Zhang J, Zhang J, Cui X, Yang Y, Li M, Qu J, Li J and Wang J: FoxM1: A novel tumor biomarker of lung cancer. Int J Clin Exp Med. 8:3136–3140. 2015.PubMed/NCBI
40	Diaz LK, Zhou X, Welch K, Sahin A and Gilcrease MZ: Chromogenic in situ hybridization for alpha6beta4 integrin in breast cancer: Correlation with protein expression. J Mol Diagn. 6:10–15. 2004. View Article : Google Scholar : PubMed/NCBI
41	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
42	Karlsen MA, Høgdall EV, Christensen IJ, Borgfeldt C, Kalapotharakos G, Zdrazilova-Dubska L, Chovanec J, Lok CA, Stiekema A, Mutz-Dehbalaie I, et al: A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer-An international multicenter study in women with an ovarian mass. Gynecol Oncol. 138:640–646. 2015. View Article : Google Scholar : PubMed/NCBI
43	Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A and Isola JJ: Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res. 6:1833–1839. 2000.PubMed/NCBI
44	Katz B, Tropé CG, Reich R and Davidson B: MicroRNAs in ovarian cancer. Hum Pathol. 46:1245–1256. 2015. View Article : Google Scholar : PubMed/NCBI
45	van Jaarsveld MT, Helleman J, Berns EM and Wiemer EA: MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol. 42:1282–1290. 2010. View Article : Google Scholar : PubMed/NCBI
46	Chong GO, Jeon HS, Han HS, Son JW, Lee YH, Hong DG, Lee YS and Cho YL: Differential microRNA expression profiles in primary and recurrent epithelial ovarian cancer. Anticancer Res. 35:2611–2617. 2015.PubMed/NCBI
47	Donadini A, Giacopelli F, Ravazzolo R, Gandin V, Marchisio PC and Biffo S: GABP complex regulates transcription of eIF6 (p27BBP), an essential trans-acting factor in ribosome biogenesis. FEBS Lett. 580:1983–1987. 2006. View Article : Google Scholar : PubMed/NCBI
48	Ristevski S, O'Leary DA, Thornell AP, Owen MJ, Kola I and Hertzog PJ: The ETS transcription factor GABPalpha is essential for early embryogenesis. Mol Cell Biol. 24:5844–5849. 2004. View Article : Google Scholar : PubMed/NCBI
49	Ristola M, Arpiainen S, Shimokawa T, Ra C, Tienari J, Saleem MA, Holthöfer H and Lehtonen S: Regulation of nephrin gene by the Ets transcription factor, GA-binding protein. Nephrol Dial Transplant. 28:846–855. 2012. View Article : Google Scholar : PubMed/NCBI
50	Yu S, Cui K, Jothi R, Zhao DM, Jing X, Zhao K and Xue HH: GABP controls a critical transcription regulatory module that is essential for maintenance and differentiation of hematopoietic stem/progenitor cells. Blood. 117:2166–2178. 2011. View Article : Google Scholar : PubMed/NCBI
51	Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: Cell fate control and intergration in development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
52	Radtke F, MacDonald HR and Tacchini-Cottier F: Regulation of innate andadaptive immunity by Notch. Nat Rev Immunol. 13:427–437. 2013. View Article : Google Scholar : PubMed/NCBI
53	Ranganathan P, Weaver KL and Capobianco AJ: Notch signalling in solid tumours: A little bit of everything but not all the time. Nat Rev Cancer. 11:338–351. 2011. View Article : Google Scholar : PubMed/NCBI
54	Lin JT, Chen MK, Yeh KT, Chang CS, Chang TH, Lin CY, Wu YC, Su BW, Lee KD and Chang PJ: Association of high levels of Jagged-1 and Notch-1 expression with poor prognosis in head and neck cancer. Ann Surg Oncol. 17:2976–2983. 2010. View Article : Google Scholar : PubMed/NCBI
55	Ranganathan P, Weaver KL and Capobianco AJ: Notch signalling in solid tumours: A little bit of everything but not all the time. Nat Rev Cancer. 11:338–351. 2011. View Article : Google Scholar : PubMed/NCBI
56	Bell D, Hanna EY, Miele L, Roberts D, Weber RS and El-Naggar AK: Expression and significance of notch signaling pathway in salivary adenoid cystic carcinoma. Ann Diagn Pathol. 18:10–13. 2014. View Article : Google Scholar : PubMed/NCBI
57	Zardawi SJ, Zardawi I, McNeil CM, Millar EK, McLeod D, Morey AL, Crea P, Murphy NC, Pinese M, Lopez-Knowles E, et al: High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology. 56:286–296. 2010. View Article : Google Scholar : PubMed/NCBI
58	Arya M, Thrasivoulou C, Henrique R, Millar M, Hamblin R, Davda R, Aare K, Masters JR, Thomson C, Muneer A, et al: Targets of Wnt/ß-catenin transcription in penile carcinoma. PLos One. 10:e01243952015. View Article : Google Scholar : PubMed/NCBI
59	Clevers H and Nusse R: Wnt/b-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
60	Polakis P: Drugging Wnt signaling in cancer. EMBO J. 31:2737–2746. 2012. View Article : Google Scholar : PubMed/NCBI
61	Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S, Heck AJ, Maurice MM, Mahmoudi T and Clevers H: Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell. 149:1245–1256. 2012. View Article : Google Scholar : PubMed/NCBI
62	Niehrs C and Acebron SP: Mitotic and mitogenic Wnt signalling. EMBO J. 31:2705–2713. 2012. View Article : Google Scholar : PubMed/NCBI
63	Klaus A and Birchmeier W: Wnt signaling and its impact on development and cancer. Nat Rev Cancer. 8:387–398. 2008. View Article : Google Scholar : PubMed/NCBI
64	Higgs MR, Lerat H and Pawlotsky JM: Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events. Oncogene. 32:4683–4693. 2013. View Article : Google Scholar : PubMed/NCBI
65	Wang H, Wang H, Makki MS, Wen J, Dai Y, Shi Q, Liu Q, Zhou X and Wang J: Overexpression of β-catenin and cyclinD1 predicts a poor prognosis in ovarian serous carcinomas. Int J Clin Exp Pathol. 7:264–271. 2013.PubMed/NCBI
66	Ji Y, Shah S, Soanes K, Islam MN, Hoxter B, Biffo S, Heslip T and Byers S: Eukaryoticinitiation factor 6 selectively regulates Wnt signaling and beta-catenin protein synthesis. Oncogene. 27:755–762. 2008. View Article : Google Scholar : PubMed/NCBI
67	Sahai E and Marshall CJ: Rho GTPases and cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar : PubMed/NCBI
68	Pedersen E and Brakebusch C: Rho GTPase function in development: How in vivo models change our view. Exp Cell Res. 318:1779–1787. 2012. View Article : Google Scholar : PubMed/NCBI
69	Reymond N, Riou P and Ridley AJ: Rho GTPases and cancer cell transendothelial migration. Methods Mol Biol. 827:123–142. 2012. View Article : Google Scholar : PubMed/NCBI
70	Stengel K and Zheng Y: Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal. 23:1415–1423. 2011. View Article : Google Scholar : PubMed/NCBI
71	Bray K, Gillette M, Young J, Loughran E, Hwang M, Sears JC and Vargo-Gogola T: Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration. Breast Cancer Res. 15:R912013. View Article : Google Scholar : PubMed/NCBI
72	Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, et al: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 8:979–986. 2002. View Article : Google Scholar : PubMed/NCBI
73	Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, et al: eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA. 107:pp. 14134–14139. 2010; View Article : Google Scholar : PubMed/NCBI
74	Cope CL, Gilley R, Balmanno K, Sale MJ, Howarth KD, Hampson M, Smith PD, Guichard SM and Cook SJ: Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J Cell Sci. 127:788–800. 2014. View Article : Google Scholar : PubMed/NCBI
75	Grosso S, Pesce E, Brina D, Beugnet A, Loreni F and Biffo S: Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1. PLoS One. 6:e291362011. View Article : Google Scholar : PubMed/NCBI